NSE filing, NSE: FWSTC. Summary written from the filing by ALFA Finder's alert engine.
Flywings Simulator Training Centre Ltd: key numbers
- Share price
- ₹251.45
- Market cap
- ₹255.9 Cr
- Revenue (annual)
- ₹24.51 Cr
- Net profit (annual)
- ₹11.64 Cr
- P/E (TTM)
- 22.0×Sector 34.1×
- Promoter holding
- 59.87%
- FII holding
- 1.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Flywings Simulator Training Centre Ltd
All →Flywings Simulator Training Centre Capacity Expansion
Flywings Simulator Training Centre announced the upcoming launch of its new flying school at Dholera International Airport, Gujarat, as part of its aviation training expansion.
Flywings Simulator Training Centre Other Announcement
Flywings Simulator Training Centre corrected an inadvertent error in its FY26 earnings call transcript. Captain Sanjay Mandavia's designation was wrongly stated as CEO; no management change exists.
Flywings Simulator Training Centre Annual General Meeting
Flywings Simulator Training Centre Limited has issued a notice for an Extra-Ordinary General Meeting (EGM) scheduled for November 05, 2026, to be held via video conferencing.
Flywings Simulator Training Centre Board Meeting Outcome
Flywings Simulator Training Centre Ltd's board approved altering its Memorandum of Association to add transportation and mobility objects. An EGM is convened for 5th November 2026.
Flywings Simulator Training Centre Board Meeting Date
Flywings Simulator Training Centre Ltd has cancelled its board meeting originally scheduled for October 8, 2026. The company will announce a revised meeting date later.
Flywings Simulator Training Centre Regulatory Approval
Flywings Simulator Training Centre Ltd received DGCA approval to conduct Safety and Emergency Procedures (SEP) practical training at its Gurugram facility for one year.
- From
- Directorate General of Civil Aviation (DGCA)
- Execution
- 1 year
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.